Abstract

Cancer is conventionally described as uncontrolled cell growth — a gain of function. We argue it is more precisely characterized as the loss of a stop signal: the cell cycle activates but cannot complete, because the checkpoint mechanism that issues the stand-down instruction is broken. In approximately half of all human cancers, this broken checkpoint is a point mutation in TP53.

The minimum intervention is to restore that nucleotide. A base editor converts the mutant base back to wild-type at the endogenous locus, under the native promoter. The cell regains the stop signal it lost. It stops itself.

---

1. Introduction

1.1 The cell cycle as a parsimonious system

1. receive    — growth signal detected, cell enters cycle
2. replicate  — DNA copied
3. checkpoint — damage assessed; p53 issues stop signal if needed
4. resolve    — cell divides cleanly, or undergoes apoptosis

p53 acts as the gatekeeper at the G1/S and G2/M checkpoints. On detecting DNA damage, oncogene activation, or replication stress, p53 binds DNA and activates transcription of p21 (cell cycle arrest), BAX/PUMA (apoptosis), and MDM2 (negative feedback). This is a complete cycle — the cell activates, checks, and resolves.

1.2 Cancer as disruption of step 3

TP53 is mutated in approximately 50% of human cancers — more than any other gene. The vast majority are missense mutations in the DNA binding domain, clustered at six hotspot codons (R175, G245, R248, R249, R273, R282). These mutations produce a protein that cannot bind DNA and cannot activate transcription. The checkpoint cannot issue the stop signal. The cell divides without resolution.

1.3 The minimum intervention

Restore that nucleotide.

Not kill the cell. Not introduce a synthetic pathway. Convert the mutant base back to wild-type, restore p53 DNA-binding function, and allow the cell's native checkpoint machinery to complete the cycle.

---

2. Target Mutations

Mutation	Codon change	Editor	Prevalence
R175H	CGT → CAT	ABE	~5%
R248W	CGG → TGG	CBE	~5%
R248Q	CGG → CAG	ABE	~4%
R273H	CGT → CAT	ABE	~5%
R273C	CGT → TGT	CBE	~3%
R282W	CGG → TGG	CBE	~3%

ABE = adenine base editor (A→G); CBE = cytosine base editor (C→T). These cover approximately 25% of all TP53-mutant cancers with two editor types.

---

3. Proposed Intervention

3.1 Delivery

Lipid nanoparticles packaging base editor mRNA and sgRNA. For hematologic malignancies, systemic LNP delivery reaches circulating and bone marrow cells. For solid tumors, intratumoral injection provides high local concentration. Tumor-homing LNP modifications (EGFR, folate receptor, HER2 targeting) enable solid tumor delivery.

LNP payload:
  ABE8e mRNA (or BE4max mRNA)
  sgRNA targeting mutant codon

Target: endogenous TP53 locus
Edit: single nucleotide reversion to wild-type
Expression: native TP53 promoter (unchanged)

3.2 Predicted mechanism

1. receive    — growth signal, cell enters cycle (unchanged)
2. replicate  — DNA copied (unchanged)
3. checkpoint — p53 (restored) binds DNA, activates p21 / BAX  ← RESTORED
4. resolve    — cell arrests or undergoes apoptosis

The cell stops itself. No exogenous kill signal required.

---

4. Discussion

4.1 The resistance problem reframed

Standard therapies select for resistance because they impose external pressure without restoring the broken step. A tumor cell that survives chemotherapy found a way to tolerate DNA damage — it is more broken, not less.

A tumor cell with restored p53 has regained a functional checkpoint. Under replication stress, it will stop or die — by design. The selection pressure inverts: cells with restored p53 gain fitness not by further mutation but by correct function.

4.2 Testable predictions

1. Edited T-cells will express p21 and BAX in response to DNA damage within 48 hours of editing, at rates matching isogenic wild-type cells.

2. In TP53-mutant tumor xenografts, LNP delivery will produce measurable p53 reversion at >20% allele frequency within 7 days, with tumor growth arrest following.

3. Edited tumors will not show increased secondary resistance mutations after treatment, unlike chemotherapy-treated controls.

---

5. Conclusion

Cancer — in p53-mutant tumors — is a cycle with a broken step: the checkpoint exists, the machinery exists, but the protein that issues the stop signal has been disabled by a single nucleotide change.

One base. One reversion. One step restored. The cell stops itself.